ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CD38 Monoclonal Antibody SCTC21C

Its studies are mostly in Lupus Erythematosus, Systemic · Amyloidosis · Multiple Myeloma · Glomerulonephritis, IGA · Hematologic Neoplasms, led by Sinocelltech Group.

Drug pageAnti-CD38 Monoclonal Antibody SCTC21C: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 3, 20255 company-led studies, 5 open or runningNext primary completion: Apr 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group55 open or runningphase 3since Dec 3, 2025Jan 31, 2024Apr 2027phase 2 · NCT07538154

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2024First study: phase 1 study in RecurrenceFirst studyNCT06252298 · 74 planned · China
  2. Jan 2, 2025Phase 2 study in Glomerulonephritis, IGANCT06774664 · 99 planned · China
  3. Dec 3, 2025Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07297329 · 292 planned · China
  4. Jan 28, 2026Phase 3 study in AmyloidosisNCT07388602 · 90 planned · China
  5. Apr 12, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07538154 · 159 planned

Ahead

  1. Apr 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07538154
  2. Sep 2027Primary completion: phase 2 study in Glomerulonephritis, IGANCT06774664
  3. Dec 2027Primary completion: phase 3 study in AmyloidosisNCT07388602
  4. Dec 2027Primary completion: phase 3 study in Multiple MyelomaNCT07297329

TargetBeta

CD38 →read by rule
“A monoclonal antibody that targets the cell surface glycoprotein CD38, ”NCIt, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
felzartamabruleBiogenphase 315
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07538154Lupus Erythematosus, Systemic2Not yet recruitingApr 2027159
NCT07388602Amyloidosis · China3RecruitingDec 202790
NCT07297329Multiple Myeloma · China3RecruitingDec 2027292
NCT06774664Glomerulonephritis, IGA · China2Not yet recruitingSep 202799
NCT06252298Recurrence · China1RecruitingAug 28, 202574

How it is read

Names in the registry

  • “SCTC21C”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.